Halozyme Therapeutics, Inc.
HALOHalozyme Therapeutics, Inc.
NASDAQ
Healthcare
Biotechnology
$64.47
-0.93(-1.4%)
52W $47.91 – $81.23
AI-generated
Halozyme Therapeutics, Inc.
Revenue breakdown: Royalty (41.1%), Product (21.3%), Proprietary Products Sales (10.7%).
$7.6BMkt Cap
$1.4BRev TTM
$318MNI TTM
23.3xP/E TTM
Latest Earnings
10-K
FY FY2025Feb 16, 2026Halozyme Therapeutics, Inc. reported strong financial performance for the fiscal year ended December 31, 2025, with total revenues reaching $1.40 billion. The company achieved significant profitability, reporting operating income of $469.0 million and net income of $316.9 million, resulting in basic and diluted earnings per share of $3.00. Operating performance was impacted by substantial one-time expenses, including $284.9 million for...
What Changed Recently
Fundamentals
How The Business Makes Money
Revenue by Segment
Royalty41.1%($1.9B)
Product21.3%($981M)
Proprietary Products Sales10.7%($492M)
Collaborative Agreements8.1%($374M)
Bulk R Hu PH207.3%($335M)
Event Based Development And Regulatory Milestone And Other Fees4.1%($189M)
Device Partnered Products3.3%($154M)
Salesbasedmilestone2.2%($100M)
Upfront Fees1%($47M)
Device Licensing And Development0.8%($38M)
Revenue by Geography
US64.8%($2.1B)
CH19.7%($638M)
BE11.1%($360M)
JP2.5%($80M)
Foreign Other1.9%($62M)
Analyst View
Company Profile
CIK0001159036
ISINUS40637H1095
CUSIP40637H109
Phone858 794 8889
Address11388 Sorrento Valley Road, San Diego, CA, 92121, US
SEC EDGAR